Profile data is unavailable for this security.
About the company
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
- Revenue in USD (TTM)20.25bn
- Net income in USD2.00bn
- Incorporated1906
- Employees75.00k
- LocationBecton Dickinson and Co1 Becton DrFRANKLIN LAKES 07417-1815United StatesUSA
- Phone+1 (201) 847-6800
- Websitehttp://www.bd.com/
Mergers & acquisitions
| Acquired company | BDX:NYQ since announced | Transaction value |
|---|---|---|
| Scanwell Health Inc | 4.84% | -- |
| Tissuemed Ltd | 7.38% | -- |
| Venclose Inc | 9.50% | -- |
| Tepha Inc | 6.09% | -- |
| Velano Vascular Inc | 7.03% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DexCom, Inc. | 2.32bn | 529.30m | 40.91bn | 5.50k | 79.35 | 19.15 | 66.03 | 17.64 | 5.32 | 5.32 | 23.26 | 22.04 | 0.5388 | 2.54 | 5.16 | 421,672.70 | 12.30 | 5.78 | 14.37 | 6.78 | 69.77 | 66.09 | 22.82 | 7.98 | 4.50 | 3.86 | 0.4519 | 0.00 | 30.54 | 36.81 | 388.23 | -- | 42.98 | -- |
| Baxter International Inc | 12.45bn | 1.21bn | 43.20bn | 50.00k | 36.21 | 4.93 | 20.75 | 3.47 | 2.38 | 2.38 | 24.38 | 17.52 | 0.624 | 3.73 | 6.11 | 249,020.00 | 6.13 | 10.83 | 7.43 | 13.31 | 39.91 | 41.88 | 9.83 | 17.19 | 1.78 | 15.44 | 0.4032 | 20.45 | 2.74 | 3.21 | 36.56 | 22.90 | -4.89 | -5.54 |
| Boston Scientific Corporation | 11.47bn | 1.10bn | 61.23bn | 38.00k | 55.95 | 3.72 | 27.92 | 5.34 | 0.768 | 0.768 | 8.01 | 11.55 | 0.3657 | 2.47 | 7.02 | 301,842.10 | 3.69 | 3.03 | 4.18 | 3.78 | 66.96 | 69.70 | 10.09 | 7.17 | 1.15 | -- | 0.3556 | 0.00 | -7.66 | 5.80 | -119.23 | -- | 0.3484 | -- |
| Edwards Lifesciences Corp | 5.09bn | 1.48bn | 70.33bn | 14.90k | 48.27 | 12.69 | 43.64 | 13.81 | 2.33 | 2.33 | 8.04 | 8.88 | 0.681 | 1.64 | 8.86 | 341,912.80 | 19.75 | 14.69 | 22.47 | 17.48 | 75.74 | 74.51 | 29.00 | 21.52 | 2.87 | -- | 0.097 | 0.00 | 0.8809 | 11.96 | -21.56 | 10.72 | 30.77 | -- |
| Becton Dickinson and Co | 20.25bn | 2.00bn | 75.43bn | 75.00k | 38.65 | 3.18 | 17.65 | 3.73 | 6.85 | 6.85 | 69.36 | 83.23 | 0.3754 | 3.86 | 8.27 | 269,960.00 | 3.88 | 2.61 | 4.39 | 2.96 | 46.56 | 46.63 | 10.33 | 7.49 | 0.9013 | 7.02 | 0.4265 | 72.79 | 18.29 | 10.16 | 161.02 | 15.45 | 11.39 | 4.69 |
| Stryker Corporation | 16.67bn | 1.90bn | 96.04bn | 43.00k | 51.20 | 6.78 | 33.40 | 5.76 | 4.97 | 4.97 | 43.64 | 37.59 | 0.5018 | 1.81 | 6.36 | 387,651.20 | 5.72 | 7.32 | 6.63 | 8.72 | 62.65 | 65.69 | 11.40 | 13.78 | 1.35 | -- | 0.4715 | 39.73 | -3.58 | 7.61 | -23.24 | 2.13 | 12.52 | 10.76 |
| Intuitive Surgical, Inc. | 5.71bn | 1.70bn | 96.21bn | 8.08k | 57.81 | 8.05 | 60.50 | 16.85 | 4.66 | 4.66 | 15.61 | 33.48 | 0.4619 | 2.95 | 8.00 | -- | 13.98 | 13.97 | 15.62 | 15.60 | 69.32 | 68.83 | 30.26 | 29.07 | 5.86 | -- | -- | -- | 31.01 | 16.10 | 54.46 | 17.28 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2021 | 22.96m | 8.06% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2021 | 15.44m | 5.42% |
| Wellington Management Co. LLPas of 30 Sep 2021 | 14.49m | 5.08% |
| BlackRock Fund Advisorsas of 30 Sep 2021 | 13.37m | 4.69% |
| SSgA Funds Management, Inc.as of 30 Sep 2021 | 12.22m | 4.29% |
| Morgan Stanley Investment Management Ltd.as of 30 Sep 2021 | 8.18m | 2.87% |
| Parnassus Investmentsas of 30 Sep 2021 | 4.71m | 1.65% |
| Massachusetts Financial Services Co.as of 30 Sep 2021 | 4.44m | 1.56% |
| Geode Capital Management LLCas of 30 Sep 2021 | 4.35m | 1.53% |
| Generation Investment Management LLPas of 30 Sep 2021 | 3.79m | 1.33% |
